Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

PubWeight™: 1.26‹?› | Rank: Top 10%

🔗 View Article (PMC 3471365)

Published in Circ Cardiovasc Qual Outcomes on July 10, 2012

Authors

Sebastian Schneeweiss1, Joshua J Gagne, Amanda R Patrick, Niteesh K Choudhry, Jerry Avorn

Author Affiliations

1: Department of Medicine, Harvard Medical School, Boston, MA, USA. schneeweiss@post.harvard.edu

Articles citing this

Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis. J Gen Intern Med (2013) 1.09

Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc (2015) 1.06

Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol (2015) 0.93

New oral anticoagulants for atrial fibrillation: are they worth the risk? P T (2014) 0.87

Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses. HSR Proc Intensive Care Cardiovasc Anesth (2013) 0.84

Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. J Thromb Thrombolysis (2013) 0.83

Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clin Pharmacol (2016) 0.80

Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol. BMJ Open (2015) 0.79

How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Ann Hematol (2015) 0.77

Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis. PLoS One (2015) 0.77

Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2. SAGE Open Med (2015) 0.76

Assessing the relative efficacy of new drugs: an emerging opportunity. Nat Rev Drug Discov (2015) 0.75

Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. BMC Cardiovasc Disord (2017) 0.75

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study. Medicine (Baltimore) (2016) 0.75

Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation. Circ Cardiovasc Qual Outcomes (2017) 0.75

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US. Clinicoecon Outcomes Res (2016) 0.75

Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial. BMC Fam Pract (2016) 0.75

Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation. Drugs Real World Outcomes (2016) 0.75

Risk impact of edoxaban in the management of stroke and venous thromboembolism. Vasc Health Risk Manag (2016) 0.75

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients. J Am Heart Assoc (2017) 0.75

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. J Am Heart Assoc (2017) 0.75

Articles cited by this

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol (1997) 9.01

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ (2003) 6.61

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol (2012) 3.55

Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J (2010) 2.46

Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol (2007) 2.38

In defense of pharmacoepidemiology--embracing the yin and yang of drug research. N Engl J Med (2007) 2.15

Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ (2011) 1.86

Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther (2011) 1.59

Availability of comparative efficacy data at the time of drug approval in the United States. JAMA (2011) 1.21

Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. Am J Manag Care (2004) 1.17

Articles by these authors

Variable selection for propensity score models. Am J Epidemiol (2006) 10.68

A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77

Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44

High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40

A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31

Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19

Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA (2008) 6.63

Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57

A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47

Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95

Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68

Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51

New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30

Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16

Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. JAMA (2007) 4.11

A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98

Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85

Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82

The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med (2006) 3.75

The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64

Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62

Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43

The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34

Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33

Online social networking by patients with diabetes: a qualitative evaluation of communication with Facebook. J Gen Intern Med (2010) 3.31

The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27

Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22

Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16

Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13

Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09

Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98

University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA (2005) 2.95

Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91

Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82

Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81

Internet marketing of herbal products. JAMA (2003) 2.77

Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77

Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74

Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71

Sending pharma better signals. Science (2005) 2.69

Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65

Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res (2003) 2.65

The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol (2011) 2.61

Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA (2011) 2.60

Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58

Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56

Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55

Patients' perceptions of generic medications. Health Aff (Millwood) (2009) 2.54

Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med (2015) 2.53

Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med (2004) 2.52

Statin adherence and risk of accidents: a cautionary tale. Circulation (2009) 2.47

Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation (2008) 2.42

Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology (2005) 2.38

Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37

Racial differences in screening for prostate cancer in the elderly. Arch Intern Med (2004) 2.34

Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31

Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum (2003) 2.30

Variability in pharmacy interpretations of physician prescriptions. Med Care (2009) 2.18

Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum (2007) 2.18

Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol (2002) 2.15

Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med (2012) 2.13

Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making (2006) 2.12

Trouble getting started: predictors of primary medication nonadherence. Am J Med (2011) 2.09

Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. J Clin Epidemiol (2002) 2.09

Origins of medical innovation: the case of coronary artery stents. Circ Cardiovasc Qual Outcomes (2012) 2.08

Does this patient with a pericardial effusion have cardiac tamponade? JAMA (2007) 2.04

Every clinician deserves an un-sales rep. MedGenMed (2007) 2.03

Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf (2013) 2.01

The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology (2011) 2.01

Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.95

The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Aff (Millwood) (2009) 1.95

Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med (2012) 1.94

Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum (2006) 1.94

Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis (2011) 1.92

Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf (2009) 1.91

Preoperative statin use and postoperative acute kidney injury. Am J Med (2012) 1.87

Unregulated private markets for health care in Canada? Rules of professional misconduct, physician kickbacks and physician self-referral. CMAJ (2004) 1.85

A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol (2005) 1.83

Modes of delivery for interventions to improve cardiovascular medication adherence. Am J Manag Care (2010) 1.83

The variability and quality of medication container labels. Arch Intern Med (2007) 1.83

Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med (2011) 1.82